secwatch.observer — SEC 8-K summary
======================================

Issuer:     NKGen Biotech, Inc. (—)
CIK:        0001845459
Form:       8-K
Filed at:   2026-04-21T23:59:59+00:00
Accession:  0001213900-26-046267
Event type: debt
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.03, 3.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NKGen Biotech enters $39.9M secured convertible loan with AlpineBrook; conversion at $0.08/share
--------------------------------------------------------------------------------

- Loan of $39,922,134 refinances existing notes and provides $350,000 new cash for operations.
- Convertible at $0.08 per share; 12% interest, one-year maturity, with 20% change-of-control premium.
- Lender issued warrant for up to 3x principal/conversion price shares at $0.08, ten-year term.
- Company must increase authorized shares to allow conversion/warrant exercise; board size fixed at nine.
- NKGen has limited cash and continues seeking additional funding; security includes IP and 65% of NKGen Korea.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1845459/000121390026046267/0001213900-26-046267-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1845459/000121390026046267/ea0286919-8k_nkgen.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-046267

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer